Results 31 to 40 of about 38,272 (314)
Inhibitor binding mode and allosteric regulation of Na+-glucose symporters. [PDF]
, 2018 Sodium-dependent glucose transporters (SGLTs) exploit sodium gradients to transport sugars across the plasma membrane. Due to their role in renal sugar reabsorption, SGLTs are targets for the treatment of type 2 diabetes.
Althoff, Thorsten +9 more
core +2 more sources
Heliyon, 2023 Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinically reduce atherosclerosis and lower blood pressure. However, their impact on endothelial dysfunction in type 2 diabetes (T2D) remains unclear.
Shi Tai +8 more
doaj +1 more source
SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]
, 2016 OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila +2 more
core +2 more sources
New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]
, 2018 Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J. +2 more
core +7 more sources
Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease [PDF]
, 2017 BACKGROUND: The sodium–glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes.
Cain, V +5 more
core +1 more source
Frontiers in Pharmacology, 2021 Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms.
Dong-Yuan Chang +11 more
doaj +1 more source
Baseline characteristics and enrichment results from the SONAR trial [PDF]
, 2018 Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the urinary albumin‐to‐creatinine ratio [UACR]) and safety/
Andress, Dennis L. +15 more
core +3 more sources
Circulation, 2023 BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear ...
B. Borlaug +8 more
semanticscholar +1 more source
Cardiovascular Diabetology, 2023 Background This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation.
Akihiko Koshino +10 more
doaj +1 more source
Results of the DAPA-CKD trial and their impact on clinical practice
Mìžnarodnij Endokrinologìčnij Žurnal, 2023 Chronic kidney disease (CKD) is a growing medical and social problem in the world. Data from population base studies demonstrate an increase in the prevalence of CKD and mortality. One of the causes is an increase in the number of patients with diabetes.
O.V. Bilchenko
doaj +1 more source